European Commission extends marketing authorization for Zevalin

05/14/2008 | Pharmaceutical Online

Zevalin now has marketing authorization from the European Commission for treating untreated follicular lymphoma patients after remission induction, according to a news release from Bayer Schering Pharma. "It is particularly impressive that with one single infusion of Zevalin, we have achieved prolongation of median progression-free survival by two years, with a favorable toxicity profile," said an investigator in a study of the drug.

View Full Article in:

Pharmaceutical Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX